Telesis Bio manufactures and sells laboratory equipment, synthetic biology instruments, reagents and associated products and related services to pharmaceutical and academic laboratories. Co.'s solutions include: BioXp 3250 and BioXp 9600 systems, which are an end-to-end automated workstation that enables researchers to go from a DNA sequence to endpoint-ready DNA; BioXp DBC, which is an enzymatic DNA synthesis with design to endpoint-ready synthetic RNA; BioXp portal, which is an online portal that provides guided workflow and design tools for building new DNA sequences; and BioXp De Novo kits, contain the building blocks and reagents for synthetic biology workflow applications. The TBIO average annual return since 2021 is shown above.
The Average Annual Return on the TBIO average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TBIO average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|